Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Audie Soucy
Celltrion and Genuv Partner to Develop Novel Therapeutic Antibodies
Celltrion and Genuv Inc., a Seoul-based a clinical-stage biotechnology company focused on drug discovery, entered a partnership last week to develop novel therapeutic antibodies using Genuv’s SHINE MOUSE platform. Under the terms of agreement, Genuv will conduct antibody discovery service using the SHINE MOUSE technology to be followed by research collaboration. According to Genuv, the SHINE MOUSE platform is able to generate a greater diversity of antibodies than conventional mice.
Celltrion and Genuv Partner to Develop Novel Therapeutic Antibodies
Celltrion and Genuv Inc., a Seoul-based a clinical-stage biotechnology company focused on drug discovery, entered a partnership last week to develop novel therapeutic antibodies using Genuv’s SHINE MOUSE platform. Under the terms of agreement, Genuv will conduct antibody discovery service using the SHINE MOUSE technology to be followed by research collaboration. According to Genuv, the SHINE MOUSE platform is able to generate a greater diversity of antibodies than conventional mice.
Genentech BPCIA Trastuzumab Case Against Tanvez Dismissed After Settlement
As previously reported, Genentech and Tanvex reached an agreement in January 2022 to settle BPCIA litigation relating to Tanvex’s biosimilar of HERCEPTIN (trastuzumab). On February 9, the court entered an order dismissing all claims in the case. Tanvez’s trastuzumab biosimilar has not yet been approved by FDA. Genentech previously settled cases filed against Pfizer, Celltrion/Teva, Amgen, and Samsung Bioepis/Merck involving their respective trastuzumab biosimilars.
Alvotech And STADA Launch HUKYNDRA® (Biosimilar Of HUMIRA®) In Europe
Alvotech and Stada recently announced the launch of HUKYNDRA® to patients in certain European countries, including France, Germany, Finland, and Sweden. HUKYNDRA® is a biosimilar of HUMIRA® (adalimumab) developed by Alvotech and is authorized for the treatment of a range of inflammatory conditions including psoriasis, Crohn's disease, and ulcerative colitis.
Alvotech and STADA Launch HUKYNDRA® (Biosimilar of HUMIRA®) in Europe
Alvotech and Stada recently announced the launch of HUKYNDRA® to patients in certain European countries, including France, Germany, Finland, and Sweden. HUKYNDRA® is a biosimilar of HUMIRA® (adalimumab) developed by Alvotech and is authorized for the treatment of a range of inflammatory conditions including psoriasis, Crohn’s disease, and ulcerative colitis.
Q1 2022 Earnings Roundup: Biologics And Biosimilars Update
Below are some highlights from first quarter 2022 earnings reports recently released by biologics and biosimilars companies: Biogen: Last week, Biogen total quarterly revenues of $2,532 million, and biosimilar revenue of $194 million decreased 5% versus the prior year.
Alvotech And AbbVie Resolve Disputes Relating To Alvotech's Adalimumab Biosimilar In Europe
United States: Alvotech And AbbVie Resolve Disputes Relating To Alvotech's Adalimumab Biosimilar In Europe 08 April 2022 Goodwin Procter LLP Alvotech Holdings S.A. (“Alvotech”) announced today that it has resolved all intellectual property disputes with AbbVie in Europe related to Alvotech's AVT02 (adalimumab) biosimilar candidate.
Alvotech and AbbVie Resolve Disputes Relating to Alvotech’s Adalimumab Biosimilar in Europe
Alvotech Holdings S.A. (“Alvotech”) announced today that it has resolved all intellectual property disputes with AbbVie in Europe related to Alvotech’s AVT02 (adalimumab) biosimilar candidate.
Parties In Amgen v. Hospira Pegfilgrastim Litigation Stipulate To Dismissal Of All Claims
United States: Parties In Amgen v. Hospira Pegfilgrastim Litigation Stipulate To Dismissal Of All Claims 24 March 2022 Goodwin Procter LLP To print this article, all you need is to be registered or login on Mondaq.com. On March 19, 2022, the parties in the Amgen Inc. v. Hospira Inc. (D. Del., No. 20-201) NEULASTA®/pegfilgrastim litigation submitted a stipulation to dismiss all claims and counterclaims in the litigation with prejudice. The Court (Judge Connolly) entered the order of dismissal on Monday.
Parties in Amgen v. Hospira Pegfilgrastim Litigation Stipulate to Dismissal of All Claims
On March 19, 2022, the parties in the Amgen Inc. v. Hospira Inc. (D. Del., No. 20-201) NEULASTA®/pegfilgrastim litigation submitted a stipulation to dismiss all claims and counterclaims in the litigation with prejudice. The Court (Judge Connolly) entered the order of dismissal on Monday. The case has been pending since February 2020. Hospira Inc.’s NEULASTA® biosimilar, NYVEPRIA®, was approved by the FDA on June 10, 2020. NYVEPRIA® is one of four pegfilgrastim biosimilars approved in the US.
Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio
United States: Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio 08 March 2022 Goodwin Procter LLP To print this article, all you need is to be registered or login on Mondaq.com. On Monday, Biocon Biologics Limited (Biocon) announced that it will acquire Viatris' rights in biosimilars assets for up to $3.3 billion.
Biocon Biologics Ltd. To Acquire Viatris Biosimilars Portfolio
On Monday, Biocon Biologics Limited (Biocon) announced that it will acquire Viatris’ rights in biosimilars assets for up to $3.3 billion. Viatris and Biocon previously partnered to bring SEMGLEE to market in the U.S. SEMGLEE (insulin glargine-yfgn) injection launched last year in the U.S. as the first-ever interchangeable biosimilar approved by the FDA. Viatris’ portfolio , a biosimilar to AbbVie’s HUMIRA (adalimumab).
Biosimilar Cyltezo® shows similar clinical outcomes to Humira® in treatment of moderate-to-severe chronic plaque psoriaris
Boehringer Ingelheim announced earlier this week that results from a phase III study showed that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in the treatment of people with moderate-to-severe chronic plaque psoriasis. The results support Boehringer Ingelheim’s supplemental biologics application to designate Cyltezo® as an interchangeable biosimilar to Humira®. The action date is scheduled for the 4th quarter of 2021.
CytoImmune Therapeutics and Biosimilar Sciences US to Move Biotechnology Operations to Puerto Rico
With the support of the economic development organization Invest Puerto Rico, Biosimilar Solutions LLC announced that both it and CytoImmune Therapeutics will be establishing operations on the island to conduct biologics and cell therapy research and development. According to the press release, CytoImmune will relocate to Toa Baja and plans to invest $28 million in the facility, which will be developing and marketing novel cancer immunotherapy products.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Audie
Contact Audie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack